Travere Therapeutics, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $93.0M | $58.5M | $58.2M | $61.7M | $165.8M | $84.8M | $62.4M | $102.9M |
| Accounts Receivable | $80.1M | $27.1M | $21.2M | $16.6M | $15.9M | $15.9M | $18.0M | $12.7M |
| Inventory | $36.2M | $41.9M | $9.4M | $4.5M | $7.3M | $7.6M | $6.1M | $5.6M |
| Total Current Assets | $437.6M | $416.7M | $616.8M | $486.4M | $582.8M | $410.4M | $429.1M | $495.7M |
| Property, Plant & Equipment | $4.0M | $5.3M | $7.5M | $9.0M | $11.1M | $9.4M | $2.9M | $3.1M |
| Goodwill | — | $800.0K | $800.0K | $800.0K | $900.0K | $900.0K | $936.0K | $936.0K |
| Intangible Assets (Excl. Goodwill) | $113.9M | $104.0M | $104.4M | $97.1M | $148.4M | $154.1M | $157.2M | $186.7M |
| Total Assets | $605.2M | $594.1M | $788.9M | $672.6M | $776.6M | $607.4M | $604.8M | $709.2M |
| Liabilities | ||||||||
| Accounts Payable | $24.8M | $23.5M | $41.7M | $17.3M | $15.1M | $12.1M | $26.6M | $7.0M |
| Total Current Liabilities | $159.9M | $200.8M | $177.9M | $142.2M | $124.1M | $92.7M | $95.4M | $104.6M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $490.4M | $535.0M | $588.1M | $629.7M | $474.5M | $396.2M | $383.6M | $390.9M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.47B | $-1.45B | $-1.13B | $-1.01B | $-766.0M | $-585.9M | $-416.4M | $-270.0M |
| Total Stockholders' Equity | $114.8M | $59.1M | $200.8M | $42.9M | $302.1M | $211.2M | $221.2M | $318.3M |